News >

Novel CLL Regimens Show Promising Efficacy

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 19, 2019

Suman Kambhampati, MD
Suman Kambhampati, MD
BTK inhibitor–based regimens, chimeric antigen receptor (CAR) T-cell therapy, and venetoclax (Venclexta) combined with rituximab (Rituxan) are all novel, therapeutic strategies that recently showed efficacious outcomes in patients with chronic lymphocytic leukemia (CLL), according to Suman Kambhampati, MD.

State of the Science Summit™ on Hematologic Malignancies, Kambhampati, the co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, reflected on the emergence of data in CLL from the 2018 ASH Annual Meeting.

OncLive: One of your presentations at the State of the Science SummitTM was on CLL. Could you highlight what is new in this space?

Kambhampati: One of the resounding themes of the 2018 ASH Annual Meeting was the introduction of novel drugs. There were also some new themes evolving from the novel drugs, showing that compared with our traditional bones of chemoimmunotherapy, BTK inhibitors—especially ibrutinib—is a practice-changing paradigm both in the young and elderly patient populations. We saw that results were better with ibrutinib-based combinations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x